Core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 expression correlates with prostate cancer progression.

<p>(<b>A</b>) Biosynthetic pathways for <i>O</i>-glycans. (<b>B</b>) PCa specimens were incubated with an anti-core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 (GCNT1) monoclonal antibody (mAb), followed by a horseradish peroxidase (HRP)-conjugated secondary antibody. Counterstaining was performed using hematoxylin. GCNT1-positive cancer cells are brown. (<b>C</b>) Prostate-specific antigen-free survival periods were compared between GCNT1-positive and GCNT1-negative specimens. Survival was analyzed using Kaplan-Meier curves.</p

Prostate-specific antigen concentration and core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 expression predict extracapsular extension of prostate cancer.

<p>(<b>A</b>) Prostate-specific antigen (PSA) concentration and (<b>B</b>) Core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 (GCNT1) expression levels were significantly higher in prostate cancer (PCa) patients with extracapsular extension than in patients with organ-confined disease. (<b>C</b>) Receiver-operator characteristic curve analysis of PSA and GCNT1 revealed that the area under the curve of PSA was 0.7455 and GCNT1 was 0.7614. (<b>D</b>) Risk stratification was established using PSA and GCNT1 to predict the outcome of local PCa. Double negative (DN)-risk (PSA < 7.52 ng/mL, GCNT1< 79.36 pg/mg), single positive (SP)-risk (PSA > 7.52 ng/mL or GCNT1 > 79.36 pg/mg) and double positive (DP)-risk (PSA > 7.52 ng/mL and GCNT1 > 79.36 pg/mg) patients are compared.</p

Logistic regression analyses of risk factors for extracapsular extension of prostate cancer.

<p>^a; pre-treatment prostate-specific antigen</p><p>^b; Gleason score</p><p>CI, confidence interval; GCNT1, core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1; HR, hazard ratio; PSA, prostate-specific antigen</p><p>Logistic regression analyses of risk factors for extracapsular extension of prostate cancer.</p

Univariate and multivariable analyses of risk factors for prostate-specific antigen recurrence.

<p>^a, pre-treatment prostate-specific antigen</p><p>^b, Gleason score</p><p>^c, cancer existence at the resected margin</p><p>^d, perineural invasion</p><p>^e, extracapsular extension</p><p>CI, confidence interval; GCNT1, core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1; HR, hazard ratio; PSA, prostate-specific antigen.</p><p>Univariate and multivariable analyses of risk factors for prostate-specific antigen recurrence.</p

Detection of core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 in post-digital rectal examination urine specimens.

<p>(<b>A</b>) Post-digital rectal examination urine specimens were collected and (<b>B</b>) centrifuged. (<b>C</b>) Supernatants were collected and spotted onto a nitrocellulose membrane. (<b>D</b>) Core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 (GCNT1) was detected by an anti-GCNT1 monoclonal antibody, followed by a horseradish peroxidase (HRP)-conjugated antibody. (<b>E</b>) After treatment with a chemiluminescence reagent, the GCNT1 signal was recorded by a ChemiDoc+ system.</p

Predictive value of the risk stratification.

<p><b>A:</b> Patients characteristics that were significantly different between the groups (*, <i>P</i> < 0.01). Error bar demonstrated 95% CI. <b>B:</b> ROC curve analysis to determine optimal cut-off values of age, gait speed in Get-up and Go test, and fall risk assessment scores. The AUC values were 0.89 in age, 0.87 in Get-up and Go test, and 0.79 in fall risk assessment score. The optimal cut-off values were age older than 75 years, slower than 13.0 s in the Get-up and Go test, and higher than 10 points in fall risk assessment score. <b>C:</b> Patients were categorized according to the number of independent predictors (>75 years old, Get-up and Go > 13.0 s, eGFR decline > 30%) for postoperative delirium (scores 0–3). The occurrence of postoperative delirium was 0% in score 0, 1.4% in score 1, 26% in score 2, and 67% in score 3 (<i>P</i> < 0.001). <b>D:</b> Predictive accuracy of selected three factors by the ROC curve showed that the AUC value was 0.952 (<i>P</i> < 0.001, 95% CI 0.902–1.00).</p

Uni- and multivariate logistic regression analysis of independent risk factors for incident of postoperative delirium.

<p>Uni- and multivariate logistic regression analysis of independent risk factors for incident of postoperative delirium.</p

Types of surgeries.

<p>We divided our urological surgery to two groups, major and minor. Surgeries under general anesthesia and local or spinal anesthesia were regarded as major and minor, respectively.</p

Patients’ characteristics.

<p>Patients’ characteristics.</p